BR112014013640A2 - anticorpos úteis na imunização passiva contra influenza - Google Patents

anticorpos úteis na imunização passiva contra influenza

Info

Publication number
BR112014013640A2
BR112014013640A2 BR112014013640A BR112014013640A BR112014013640A2 BR 112014013640 A2 BR112014013640 A2 BR 112014013640A2 BR 112014013640 A BR112014013640 A BR 112014013640A BR 112014013640 A BR112014013640 A BR 112014013640A BR 112014013640 A2 BR112014013640 A2 BR 112014013640A2
Authority
BR
Brazil
Prior art keywords
influenza
antibodies
passive immunization
immunization against
antibodies useful
Prior art date
Application number
BR112014013640A
Other languages
English (en)
Other versions
BR112014013640A8 (pt
Inventor
Maureen Mccutcheon Krista
M Kauvar Lawrence
Park Minha
Ellsworth Stote
Usinger William
Original Assignee
Trellis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Llc filed Critical Trellis Bioscience Llc
Publication of BR112014013640A2 publication Critical patent/BR112014013640A2/pt
Publication of BR112014013640A8 publication Critical patent/BR112014013640A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo anticorpos úteis na imunização passiva contra influenza anticorpos e fragmentos de anticorpos monoclonais específicos, incluindo biespecíficas mesmos que são reações cruzadas com vários subtipos do vírus da gripe, incluindo tanto dos grupos 1 e 2 representantes são divulgados. estes anticorpos são úteis no controlo de epidemias de gripe e pandemias, bem como no fornecimento de proteção profilática ou terapêutica contra a gripe sazonal.
BR112014013640A 2011-12-05 2012-12-05 anticorpos úteis em imunização passiva para influenza BR112014013640A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567046P 2011-12-05 2011-12-05
PCT/US2012/068037 WO2013086052A2 (en) 2011-12-05 2012-12-05 Antibodies useful in passive influenza immunization

Publications (2)

Publication Number Publication Date
BR112014013640A2 true BR112014013640A2 (pt) 2017-06-13
BR112014013640A8 BR112014013640A8 (pt) 2021-03-16

Family

ID=48575054

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013640A BR112014013640A8 (pt) 2011-12-05 2012-12-05 anticorpos úteis em imunização passiva para influenza

Country Status (14)

Country Link
US (1) US10654915B2 (pt)
EP (1) EP2793945B1 (pt)
JP (1) JP6371222B2 (pt)
CN (1) CN104302321A (pt)
AU (1) AU2012347878B2 (pt)
BR (1) BR112014013640A8 (pt)
CA (1) CA2861515A1 (pt)
DK (1) DK2793945T3 (pt)
ES (1) ES2686526T3 (pt)
HK (1) HK1203410A1 (pt)
IL (1) IL232976A0 (pt)
MX (1) MX367743B (pt)
RU (1) RU2668802C2 (pt)
WO (1) WO2013086052A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
WO2014152841A1 (en) * 2013-03-14 2014-09-25 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
BR112016018082A2 (pt) * 2014-02-04 2018-02-20 Contrafect Corporation ?anticorpos úteis na imunização passiva de influenza e composições, combinações e métodos para uso dos mesmos?
WO2016011035A2 (en) * 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
MX2017015189A (es) * 2015-06-01 2018-04-13 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN116271017A (zh) 2016-01-13 2023-06-23 免疫医疗有限责任公司 治疗甲型流感的方法
KR20200115517A (ko) 2018-01-26 2020-10-07 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4625015A (en) * 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
AU2002258621A1 (en) 2001-03-28 2002-10-21 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
JP2006519775A (ja) 2003-03-07 2006-08-31 メルク　エンド　カムパニー　インコーポレーテッド インフルエンザウイルスワクチン
WO2005012360A2 (en) 2003-07-22 2005-02-10 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
KR101133910B1 (ko) * 2003-07-23 2012-04-13 후지레비오 가부시키가이샤 항-인플루엔자 ａ형 바이러스 모노클로날 항체 및 상기항체를 이용하는 면역 측정 기구
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
EP2522678A1 (en) 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
WO2008007648A1 (fr) * 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
JP5346820B2 (ja) 2007-03-13 2013-11-20 エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
US20080299151A1 (en) 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
EP3333187B1 (en) 2007-12-06 2022-06-22 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
US8114968B2 (en) 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
JP2011516423A (ja) 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ， エルエルシー ウイルス抗原に対する中和分子
CA2731686C (en) * 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
AR073072A1 (es) 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
WO2010027818A2 (en) 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
SG172333A1 (en) 2008-12-24 2011-07-28 Temasek Life Sciences Lab Ltd Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
WO2010073647A1 (ja) 2008-12-25 2010-07-01 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
AU2010247530B2 (en) * 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
WO2011117848A1 (en) 2010-03-26 2011-09-29 Pomona Ricerca S.R.L. Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
WO2011126370A1 (en) * 2010-04-09 2011-10-13 Universiteit Utrecht Holding B.V. Recombinant multimeric influenza proteins
CA2839421C (en) 2010-06-17 2019-12-03 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
MX346206B (es) 2011-07-14 2017-03-09 Crucell Holland Bv Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
WO2013114885A1 (en) 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
US8834881B2 (en) 2012-03-08 2014-09-16 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
WO2014152841A1 (en) 2013-03-14 2014-09-25 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy

Also Published As

Publication number Publication date
JP6371222B2 (ja) 2018-08-08
JP2015501815A (ja) 2015-01-19
CA2861515A1 (en) 2013-06-13
HK1203410A1 (en) 2015-10-30
AU2012347878A1 (en) 2014-07-24
AU2012347878B2 (en) 2018-05-10
RU2014127287A (ru) 2016-01-27
EP2793945A4 (en) 2015-09-09
MX367743B (es) 2019-09-04
WO2013086052A3 (en) 2013-08-08
ES2686526T3 (es) 2018-10-18
NZ626716A (en) 2017-11-24
RU2668802C2 (ru) 2018-10-02
US10654915B2 (en) 2020-05-19
BR112014013640A8 (pt) 2021-03-16
EP2793945A2 (en) 2014-10-29
US20140322210A1 (en) 2014-10-30
AU2012347878A2 (en) 2014-07-31
WO2013086052A2 (en) 2013-06-13
CN104302321A (zh) 2015-01-21
DK2793945T3 (en) 2018-09-03
IL232976A0 (en) 2014-07-31
MX2014006786A (es) 2015-03-05
EP2793945B1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
BR112014013640A2 (pt) anticorpos úteis na imunização passiva contra influenza
BR112012032185A2 (pt) anticorpos úteis na imunização passiva de influenza.
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
CY1124024T1 (el) Νεες ctla4-ig ανοσοπροσκολλητινες
ECSP11010823A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos
CO2018004321A2 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
BR112013017080A2 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112014003315A2 (pt) composições e métodos relacionados a anticorpos para a proteína a estafilocócica
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
MX2015014751A (es) Composiciones y metodos para el tratamiento de la inmunodeficiencia.
WO2013020074A3 (en) A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
CO6690760A2 (es) Variantes no lipidadas de antígenos orf2086 de neisseria meningitidis
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112016018082A2 (pt) ?anticorpos úteis na imunização passiva de influenza e composições, combinações e métodos para uso dos mesmos?
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
WO2009054708A3 (en) Antibody therapy for highly pathogenic avian influenza virus
BR112015012515A2 (pt) métodos para a indução de anticorpos
WO2013136180A3 (en) Chimeric proteins for treatment of diseases
BR112015031585A2 (pt) composição farmacêutica
EA201590782A1 (ru) Оксирановые амины

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: TRELLIS BIOSCIENCE, LLC (US)

B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 62/567,046 REIVINDICADA NO PCT/US2012/068037, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E ART 2O DA RESOLUCAO INPI 179 DE 21/02/2017. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT SER DISTINTO DAQUELES QUE DEPOSITARAM A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO DENTRO DO PRAZO DE 60 DIAS A CONTAR DA DATA DA ENTRADA DA FASE NACIONAL, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2647 DE 28/09/2021.